K240670 is an FDA 510(k) clearance for the DRI Ecstasy Plus Assay. This device is classified as a Enzyme Immunoassay, Amphetamine (Class II - Special Controls, product code DKZ).
Submitted by Microgenics Corporation (Fremont, US). The FDA issued a Cleared decision on October 30, 2024, 233 days after receiving the submission on March 11, 2024.
This device falls under the Toxicology FDA review panel. Regulated under 21 CFR 862.3100.
| 510(k) Number | K240670 FDA.gov |
| FDA Decision | Cleared Substantially Equivalent - Traditional 510(k) (SESE) |
| Date Received | March 11, 2024 |
| Decision Date | October 30, 2024 |
| Days to Decision | 233 days |
| Submission Type | Special |
| Review Panel | Toxicology (TX) |
| Summary | Summary PDF |
| Product Code | DKZ — Enzyme Immunoassay, Amphetamine |
| Device Class | Class II - Special Controls |
| CFR Regulation | 21 CFR 862.3100 |